Form 4 for VRTX Vertex Pharmaceuticals
Accepted 2025-02-12 00:00:00 ET · period of report 2025-02-10 · accession 0000875320-25-000044 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-02-12 | 2025-02-10 | VRTX | Kewalramani Reshma | CEO, Pres, Dir | F - Tax | $467.98 | -8,300 | 116.9K | -7% | -$3.88M |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-02-10 | F | D | 8,300 | $467.98 | 116,918 | D | — | — |